Hepatitis C
Tattoos Are Associated with Hepatitis C Virus Infection in the Absence of Other Risk Factors
- Details
- Category: HCV Prevention
- Published on Tuesday, 29 January 2013 00:00
Individuals with chronic hepatitis C virus (HCV) infection in New York City were about 5 times more likely to have a tattoo than people without HCV, even after traditional risk factors such as injection drug use were taken into account, researchers reported in the January 12, 2013, advance online edition of Hepatology.
Boceprevir and Telaprevir Improve Hepatitis C Treatment, Literature Reviews Find
- Details
- Category: HCV Treatment
- Published on Tuesday, 29 January 2013 00:00
Triple therapy with a direct-acting antiviral drug was more effective than pegylated interferon and ribavirin alone for people with chronic hepatitis C, but there is not yet enough data to determine many differences between boceprevir (Victrelis) and telaprevir (Incivek), or to see effects on long-term clinical outcomes, according to 2 recent medical literature reviews.
Achillion Reports Promising Data on All-oral Hepatitis C Regimen with ACH-3102
- Details
- Category: HCV Treatment
- Published on Tuesday, 08 January 2013 00:00
Achillion Pharmaceuticals this week reported interim results from an ongoing Phase 2a study of an interferon-free regimen containing its once-daily NS5A inhibitor, ACH-3102, plus ribavirin. To date, the combination appears safe and shows potent activity against hepatitis C virus (HCV).
Boehringer Ingelheim Starts Phase 3 Trial of Interferon-free Faldaprevir + BI 207127
- Details
- Category: HCV Treatment
- Published on Thursday, 24 January 2013 00:00
The Phase 3 HCVerso trial, testing an all-oral regimen containing Boehringer Ingelheim's HCV protease inhibitor faldaprevir (formerly BI 201335), polymerase inhibitor BI 207127, and ribavirin has begun enrollment, the company announced last week.
HIV+ People Who Get Hepatitis C May Experience Rapid Liver Disease Progression
- Details
- Category: HCV Sexual Transmission
- Published on Tuesday, 08 January 2013 00:00
People with HIV, especially those with advanced immune suppression, who become coinfected with hepatitis C virus (HCV) may experience rapid progression to decompensated cirrhosis and liver-related death, Mt. Sinai researchers reported in the December 21, 2012, advance edition of Clinical Infectious Diseases.
Water and Filters Used for Drug Injection May Transmit Hepatitis C Virus
- Details
- Category: HCV Prevention
- Published on Friday, 11 January 2013 00:00
Water, containers, and material used to mix and filter heroin -- not just syringes -- can harbor hepatitis C virus (HCV) and contribute to transmission among injection drug users, according to a study published in the November 5, 2012, advance edition of the Journal of Infectious Diseases.
NEJM: Sofosbuvir, ABT-450, ABT-333 Look Good in Interferon-free Hepatitis C Regimens
- Details
- Category: HCV Treatment
- Published on Thursday, 03 January 2013 00:00
Two 12-week, all-oral hepatitis C regimens -- Gilead's sofosbuvir, and Abbott's ABT-450 plus ABT-333, both with ribavirin -- produced promising cure rates in studies that have now been published in the January 3, 2013, New England Journal of Medicine.
Gilead Provides More Sofosbuvir Data, Plans for Further Hepatitis C Studies
- Details
- Category: HCV Treatment
- Published on Tuesday, 08 January 2013 00:00
Gilead Sciences this week provided updated results from the ELECTRON trial evaluating sofosbuvir, GS-5885, and ribavirin, coinciding with a presentation at a financial conference in San Francisco. The company also provided information about studies of its sofosbuvir/GS-5885 combination pill now in development.
Phase 3 Studies Show Simeprevir plus Interferon/Ribavirin Cures Most Patients in 24 Weeks
- Details
- Category: HCV Treatment
- Published on Thursday, 27 December 2012 00:00
The hepatitis C virus (HCV) protease inhibitor simeprevir (formerly TMC435) plus pegylated interferon and ribavirin produced 12-week post-treatment sustained virological response (SVR12) for about 80% of genotype 1 chronic hepatitis C patients, and most could be cured with a 24-week course of therapy, according to data released by Medivir.
More Articles...
- Hepatitis C Cirrhosis Patients with Sustained Treatment Response Have Lower Risk of Death
- AASLD 2012: Interferon Lambda Shows Good HCV Suppression, Better Tolerated than Interferon Alfa
- Telaprevir Label Gets Black Box Warning about Serious Skin Rash
- Hepatitis C Sexual Transmission Is Rare among Monogamous Heterosexual Couples
- HIV11: Sexually Transmitted HCV Rising among HIV+ Gay Men in Europe, but More Are Getting Treated
Web Design and Development by